Since December 2019, the outbreak of a new coronavirus, named 2019-nCoV, has greatly threatened the public health in China and raised great concerns worldwide. No specific treatment for this infection is currently available. We previously reported that teicoplanin, a glycopeptide antibiotic which has routinely been used in the clinic to treat bacterial infection with low toxicity, significantly inhibits the invasion of cells by Ebola virus, SARS-CoV and MERS-CoV, via specifically inhibiting the activity of cathepsin L. Here, we tested the efficacy of teicoplanin against 2019-nCoV virus infection and found that teicoplanin potently prevents the entrance of 2019-nCoV-Spike-pseudoviruses into the cytoplasm, with an IC 50 of 1.66 μM. Although the inhibitory effect upon the replication of wildtype viruses ex vivo and in vivo remains to be determined, our preliminary result indicates that the potential antiviral activity of teicoplanin could be applied for the treatment of 2019-nCoV virus infection.
Introduction
The coronaviruses are enveloped, positive sense single-stranded RNA viruses 1, 2 CoV) in the Arabian Peninsula since 2012 [3] [4] [5] [6] [7] [8] [9] . Recently a novel coronavirus outbreaks in December 2019 as the pathogenic agent that causes series of pneumonia cases in Wuhan of China has quickly raised intense attention not only in China but also internationally [10] [11] [12] [13] [14] . This novel coronavirus, named as 2019 novel coronavirus (2019-nCoV), belongs to the betacoronavirus according to the sequence released 13, 15 . Evolutionary analyses have shown that the 2019-nCoV shares 79% homology with SARS-CoV and 50% with MERS-CoV [15] [16] [17] . Given the high infectious rate and the lack of effective treatment for 2019-nCoV, it is quite urgent to develop an efficient antiviral drug for 2019-nCoV.
The spike glycoprotein (S protein) is the leading mediator of viral entry, and the important determinant of host range of coronaviruses 18 . The infection of SARS virus is initiated by the attachment of S protein to the receptor ACE2 19 , followed by cleavage with host cell protease TMPRSS2 [20] [21] [22] . The viruses are then transported through the early and late endosomes, subsequently endo/lysosomes, during which host protein extracellular proteases including cathepsin L mediates the further cleavage of S protein in endocytic vesicles [23] [24] [25] [26] . The activated S protein will then activate the fusion between viral and cell membranes and release the genome of SARS-CoV into cytoplasm.
In 2016, our team had found that teicoplanin, a routinely-used clinical glycopeptide antibiotics, significantly inhibited the cellular entry of Ebola virus, SARS-CoV, and MERS-CoV 27 . Further mechanistic studies showed that teicoplanin blocked virus entry by specifically inhibiting the activity of cathepsin L, opening a novel avenue for the development of glycopeptides as potential inhibitors of cathepsin L-dependent viruses. In this study, we have compared the cleavage site of cathepsin L in 2019-nCoV with that in SARS-CoV and found it is well conserved. Furthermore, we identified that teicoplanin also potently inhibited the entry of 2019-nCoV pseudovirus, which provide a possible strategy to the prophylaxis and treatment for2019-nCoV infection.
Materials and methods

Cell culture and recombinant viruses.
The plasmid containing spike (S) gene of 2019-nCoV was purchased from Generay Biotech company (Shanghai, China) and inserted into pcDNA3.1 vector. HIV-1/2019-nCoV-S/ pseudoviruses were produced by the co-transfection of pHIV-luciferase, psPAX2, and plasmids expressing different envelope or S proteins into HEK293T cells as previously described 27 Consensus sequences were created using the BioEdit software (http://www.mbio.ncsu.edu/bioedit/bioedit.html) based on the multiple alignment of SARS-CoV and 2019-nCoV, respectively. The amino acid sequence logos generated by using WebLogo 29 .
Statistics
Statistical analysis was performed with GraphPad Prism 7. For data with a normal distribution, we used a Student's t test. For multiple comparisons a one-way or two-way ANOVA (for parametric data) followed by Bonferroni's correction (only two groups were compared) were used. P values < 0.05 were considered statistically significant.
Results
Cathepsin L is required for the cell entry of 2019-nCoV.
The proteolytic processing of the SARS-CoV S protein is essential for the virus entry and fusion. Many cleavage sites of the relevant exogenous protease including cathepsin L and TMPRSS2 involved in the proteolytic processing of the SARS-CoV S protein have been experimentally validated 20, 30, 31 . Because cathepsin L has been identified as a target of teicoplanin, it is important to identify whether the cleavage site of cathepsin L exists on the 2019-nCOV S protein. After alignment, we found that the cleavage site of cathepsin L is well conserved between the SARS-CoV and 2019-nCoV S protein ( Figure 1A ), suggesting that cathepsin L could participant in the 2019-nCoV entry and fusion 26, 31, 32 .
Moreover, the cleavage site of cathepsin L was consistent among the epidemic strains of 2019-nCoV retrieved from the GenBank database, including 9 from Wuhan, 2 from Shenzhen, and 5 from USA ( Figure 1B ).
As such, we hypothesized that cathepsin L could be an important target for the entry of 2019-nCoV. Accordingly, we infected the cells with SARS-CoV-, or 2019-nCoV -S-pseudotyped HIV-1 viruses after siRNA-mediated knockdown of the expression of cathepsin L and TMPRSS2 and found that both cathepsin L and TMPRSS2 depletion impaired the cell entry of pseudoviruses ( Figure 1C ), indicating that both cathepsin L and TMPRSS2 are required for 2019-nCoV cell entry.
Teicoplanin specifically inhibits the entry of 2019-nCoV.
Based on our previous reported, we generated the HIV-luc/2019-nCoV-S pseudoviruses (Figure 2A Considering that ACE2 is a major receptor of 2019-nCoV, we have further analyzed the expression of ACE2 in different cell types from the GEO Profiles database and it was important to examine whether teicoplanin could repress the entry of 2019-nCoV viruses into different types of cells. The data showed that teicoplanin also effectively repressed virus entrance into HEK293T cells (Figure. 3A) , and Huh7 cells ( Figure   3B ). As we have previously demonstrated that several glycopeptide antibiotics, including teicoplanin and dalbavancin, exhibited specific inhibitory effects on cathepsin L, we therefore hypothesized that teicoplanin and its homologs could also inhibit the entry of 2019-nCoV.
The data illustrated that the dalbavancin also repressed the entry of 2019-nCoV in a dose-dependent manner ( Figure 3C ). However, vancomycin, another routinely-used antibiotics, did not inhibit the 2019-nCoV entry Teicoplanin is a glycopeptide antibiotic, which is mainly used for serious infections caused by Gram-positive bacteria such as staphylococcus aureus and streptococcus [36] [37] [38] . As a routinely-used clinical antibiotics, teicoplanin is well known for its much low toxic and side effects, long half-life in blood plasma, convenient administration, and high safety when used in combination with other antibiotics. The recommended plasma concentration of teicoplanin for clinical use to inhibit Gram-positive bacteria is 15 mg / L, or 8.78 μM, and the commonly used dose is 400 mg / day. Here we found the IC 50 inhibition of 2019-nCOV was only 1.66 uΜ, which is much lower than the routine clinical drug concentration. Therefore, the routinely-used dose (400 mg / day) could be considered for patients with 2019-nCOV infection. If the effect is not significant, dose could be optimized because of its low toxicity. The doses such as 800 mg / day or 1200 mg / day could be considered to improve the drug efficiency. Given that the principle of antiviral therapy is to prevent virus infection and amplification at a stage as early as possible, it is reasonable to recommend the use of teicoplanin 
Disclosure statement
No potential conflict of interest was reported by the authors. 
